Latest Comments

Novel Hyperkalemia Agents Race Toward the European CKD Market

Novel Hyperkalemia Agents Race Toward the European CKD Market

ESMO 2017: An uncertain future for Merck’s Keytruda

ESMO 2017: An uncertain future for Merck’s Keytruda

An update on PARP inhibitors: ovarian cancer and beyond

An update on PARP inhibitors: ovarian cancer and beyond

Array BioPharma’s BRAF/MEK combination set for approval review in Europe

Array BioPharma’s BRAF/MEK combination set for approval review in Europe

Why has the Industry seen higher numbers of Drug Designations than ever before?

Why has the Industry seen higher numbers of Drug Designations than ever before?

ESC Congress Barcelona 2017 Highlights – What is the Role of Monotherapies in the Treatment of PAH Patients?

ESC Congress Barcelona 2017 Highlights – What is the Role of Monotherapies in the Treatment of PAH Patients?

High Multiple Sclerosis Costs Are Attracting Attention From US Lawmakers

High Multiple Sclerosis Costs Are Attracting Attention From US Lawmakers

PARP inhibitors are set to become the new standard of care in BRCA1/2-mutated pancreatic adenocarcinoma

PARP inhibitors are set to become the new standard of care in BRCA1/2-mutated pancreatic adenocarcinoma

Novartis launches first smartphone-based study in MS

Novartis launches first smartphone-based study in MS

Could the first new sickle cell drug in 20 years provide hope for sufferers?

Could the first new sickle cell drug in 20 years provide hope for sufferers?

With Melinta Merger, Cempra Lands on Its Feet Despite Regulatory Struggles

With Melinta Merger, Cempra Lands on Its Feet Despite Regulatory Struggles

BMS shifts towards precision medicine

BMS shifts towards precision medicine

Dynavax’s Heplisav-B passes key regulatory hurdle with FDA Advisory Committee endorsement

Dynavax’s Heplisav-B passes key regulatory hurdle with FDA Advisory Committee endorsement

Breakthroughs for orphan designated hematological drugs could earn big revenues

Breakthroughs for orphan designated hematological drugs could earn big revenues

A vaccine for Lyme disease – second time lucky?

A vaccine for Lyme disease – second time lucky?

Tensions Rise as UK Pharma Industry Takes Government to Court

Tensions Rise as UK Pharma Industry Takes Government to Court

Strong safety and efficacy data position Aerie Pharmaceuticals to submit glaucoma NDA for Roclatan

Strong safety and efficacy data position Aerie Pharmaceuticals to submit glaucoma NDA for Roclatan

Will lampalizumab finally provide a treatment for macular degeneration?

Will lampalizumab finally provide a treatment for macular degeneration?

Gilead looks to maintain dominance in HIV with its novel STR

Gilead looks to maintain dominance in HIV with its novel STR

Arena Pharmaceuticals’ positive topline Phase II results for ralinepag pose threat for J&J’s Uptravi

Arena Pharmaceuticals’ positive topline Phase II results for ralinepag pose threat for J&J’s Uptravi

Hemophilia gene therapies impress, but pricing doubts remain

Hemophilia gene therapies impress, but pricing doubts remain